The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The Inhibition of the Highly Expressed Mir-221 and Mir-222 Impairs the Growth of Prostate Carcinoma Xenografts in Mice
Open accessAbstract
BACKGROUND: MiR-221 and miR-222 are two highly homologous microRNAs whose upregulation has been recently described in several types of human tumors, for some of which their oncogenic role was explained by the discovery of their target p27, a key cell cycle regulator. We previously showed this regulatory relationship in prostate carcinoma cell lines in vitro, underlying the role of miR-221/222 as inducers of proliferation and tumorigenicity. METHODOLOGY/PRINCIPAL FINDINGS: Here we describe a number of in vivo approaches confirming our previous data. The ectopic overexpression of miR-221 is able, per se, to confer a high growth advantage to LNCaP-derived tumors in SCID mice. Consistently, the anti-miR-221/222 antagomir treatment of established subcutaneous tumors derived from the highly aggressive PC3 cell line, naturally expressing high levels of miR-221/222, reduces tumor growth by increasing intratumoral p27 amount; this effect is long lasting, as it is detectable as long as 25 days after the treatment. Furthermore, we provide evidence in favour of a clinical relevance of the role of miR-221/222 in prostate carcinoma, by showing their general upregulation in patient-derived primary cell lines, where we find a significant inverse correlation with p27 expression. CONCLUSIONS/SIGNIFICANCE: These findings suggest that modulating miR-221/222 levels may have a therapeutic potential in prostate carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 1×
“injection of PC3 cells into SCID mice, with anti-miR-221 and anti-miR-222 ‘‘antagomirs’’, cholesterol-conjugated antisense molecules previously shown to own a good bioavailability and stability in vivo [25,26].”
BackgroundMicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer
Meng, F., Henson, R., Wehbe–Janek, H., Ghoshal, K., Jacob, S. T., & Patel, T. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.022 · Cited by 2,773
Extensive modulation of a set of microRNAs in primary glioblastoma
Ciafrè, S. A., Galardi, S., Mangiola, A., Ferracin, M., Liu, C.-G., Sabatino, G., Negrini, M., Maira, G., Croce, C. M., & Farace, M. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.030 · Cited by 1,096 · cited 1×
“Among oncomiRs, we and others previously found that miR-221 and miR-222 are involved in several different types of human neoplasms, such as glioblastoma [5–8], prostate carcinoma [9], non-small cell lung cancer [10,11], hepatocellular cancer [12,13], pancreatic cancer [14], and many others.”
BackgroundSelf-citationMicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene
Lu, Z., Liu, M., Stribinskis, V, Klinge, C. M., Ramos, K. S., Colburn, N. H., & Li, Y. (2008) · Oncogene · doi:10.1038/onc.2008.72 · Cited by 711
Cited by
MicroRNAs in Development and Disease
Sayed, D., & Abdellatif, M. (2011) · Physiological Reviews · doi:10.1152/physrev.00006.2010 · Cited by 1,078
The Potential for microRNA Therapeutics and Clinical Research
Hanna, J., Hossain, G. S., & Kocerha, J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00478 · Cited by 726
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma
Schaefer, A., Jung, M., Mollenkopf, H., Wagner, I., Stephan, C., Jentzmik, F., Miller, K., Lein, M., Kristiansen, G., & Jung, K. (2010) · International Journal of Cancer · doi:10.1002/ijc.24827 · Cited by 611
MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases
Cortez, M. A., & Calin, G. A. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902932889 · Cited by 436
Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer
Yaman Agaoglu, F., Kovancilar, M., Dizdar, Y., Darendeliler, E., Holdenrieder, S., Dalay, N., & Gezer, U. (2011) · Tumor Biology · doi:10.1007/s13277-011-0154-9 · Cited by 341
Metadata
- Authors
- Mercatelli, N., Coppola, V., Bonci, D., Miele, F., Costantini, A., Guadagnoli, M., Bonanno, E., Muto, G., Frajese, G. V., De Maria, R., Spagnoli, L. G., Farace, M. G., & Ciafrè, S. A.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-24
- Volume
- 3
- Issue
- 12
- Pages
- e4029
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2142471892
- Cited by
- 250
- References
- 4
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.